Japanese researchers yesterday described two H3N2 flu viruses with mutations that may increase resistance to the new flu antiviral baloxavir marboxil (Xofluza), approved by the US Food and Drug Administration (FDA) in October, a development they say bears watching.

Read more at CIDRAP…

See also:

Jan 17 Eurosurveill Japanese study

Jan 17 Eurosurveill US study

Oct 24, 2018, CIDRAP News scan “FDA approves Xofluza, a novel single-dose drug to treat influenza